

CME Information: Systemic mastocytosis in adults: 2015 update on diagnosis, risk-stratification, and management

Author: Animesh Pardanani M.B.B.S, Ph.D

CME Editor: Ayalew Tefferi M.D.



If you wish to receive credit for this activity, please refer to the website: www.wileyhealthlearning.com

■ Accreditation and Designation Statement:

Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Blackwell Futura Media Services designates this journal-based CME for a maximum of 1 *AMA PRA Category 1 Credit*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

■ Educational Objectives

Upon completion of this educational activity, participants will be better able to:

1. Identify the current pathogenetic concepts, classification, diagnosis and risk stratification of systemic mastocytosis.
2. Identify the current management of systemic mastocytosis, including updates in investigational therapies.

■ Activity Disclosures

No commercial support has been accepted related to the development or publication of this activity.

CME Editor: Ayalew Tefferi, M.D., has no relevant financial relationships to disclose.

Author: Animesh Pardanani, M.B.B.S, Ph.D, has no relevant financial relationships to disclose.

This activity underwent peer review in line with the standards of editorial integrity and publication ethics maintained by *American Journal of Hematology*. The peer reviewers have no conflicts of interest to disclose. The peer review process for *American Journal of Hematology* is single blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.

Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services's Policy on Activity Disclosure and Conflict of Interest. The primary resolution method used was peer review and review by a non-conflicted expert.

■ Instructions on Receiving Credit

This activity is intended for physicians. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within one hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication. Additionally, up to 3 attempts and a score of 70% or better is needed to pass the post test.

Follow these steps to earn credit:

- Log on to www.wileyhealthlearning.com
- Read the target audience, educational objectives, and activity disclosures.
- Read the activity contents in print or online format.
- Reflect on the activity contents.
- Access the CME Exam, and choose the best answer to each question.
- Complete the required evaluation component of the activity.
- Claim your Certificate.

This activity will be available for CME credit for twelve months following its launch date. At that time, it will be reviewed and potentially updated and extended for an additional twelve months.

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management

Animesh Pardanani^{1,2*}

Disease overview: Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs.

Diagnosis: The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC expression of CD25 and/or CD2, and presence of *KIT*D816V.

Risk stratification: The 2008 World Health Organization classification of SM has been shown to be prognostically relevant. Classification of SM patients into indolent SM (ISM), aggressive SM (ASM), SM associated with a clonal non-MC lineage disease (SM-AHNMD), and mast cell leukemia (MCL) subgroups is a useful first step in establishing prognosis.

Management: SM treatment is generally palliative. ISM patients have a normal life expectancy and receive symptom-directed therapy; infrequently, cytoreductive therapy may be indicated for refractory symptoms. ASM patients have disease-related organ dysfunction; interferon- α (+/–corticosteroids) can control dermatological, hematological, gastrointestinal, skeletal, and mediator-release symptoms, but is hampered by poor tolerability. Similarly, cladribine has broad therapeutic activity, with particular utility when rapid MC debulking is indicated; the main toxicity is myelosuppression. Imatinib has a therapeutic role in the presence of an imatinib-sensitive *KIT* mutation or in *KIT*D816-unmutated patients. Treatment of SM-AHNMD is governed primarily by the non-MC neoplasm; hydroxyurea has modest utility in this setting; there is a role for allogeneic stem cell transplantation in select cases.

Investigational Drugs: Recent data confirms midostaurin's significant anti-MC activity in patients with advanced SM.

Am. J. Hematol. 90:251–262, 2015. © 2015 Wiley Periodicals, Inc.



■ Disease Overview and Pathogenesis

Mastocytosis is one of eight subcategories of myeloproliferative neoplasms (MPN) per the 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues [1]. It results from a clonal, neoplastic proliferation of morphologically, and immunophenotypically abnormal mast cells (MC) that accumulate in one or more organ systems. The sine qua non of mastocytosis is the presence of multifocal clusters of abnormal MC, which in contrast to normal MC are variable in appearance, ranging from round to fusiform variants with long, polar cytoplasmic processes, and may display cytoplasmic hypogranularity with uneven distribution of fine granules, as well as atypical nuclei with monocytoid appearance [2–4].

The clinical presentation of mastocytosis is heterogeneous, ranging from skin-limited disease (cutaneous mastocytosis, CM), particularly in pediatric cases where the majority have disease-onset within the first 2 years of life and commonly experience spontaneous regression of skin lesions [5–8], to a more aggressive variant with extracutaneous involvement (systemic mastocytosis, SM) that may be associated with multiorgan dysfunction/failure and shortened survival, that is, generally seen in adult patients (Fig. 1) [9].

The WHO document distinguishes the usually *KIT*-mutated SM from a Philadelphia chromosome-negative MPN with hematological features of chronic eosinophilic leukemia associated with splenomegaly, marked elevation of serum vitamin B₁₂, elevation of serum tryptase and increased bone marrow (BM) MC commonly in scattered or noncohesive clusters [10]. The latter entity is commonly associated with rearrangement of *PDGFRA* (i.e., *FIP1L1-PDGFR*) and less commonly, *PDGFRB* (e.g., *PRKG2-PDGFRB*), and is sensitive to treatment with imatinib [11–18]. WHO-defined SM is sometimes associated with a clonally related second myeloid neoplasm [19–22], which is not surprising considering its origin as a stem cell disease with multilineage clonal involvement [23–25]. Conversely, an otherwise well-defined myeloid malignancy, such as myelodysplastic syndrome (MDS) or a non-mast cell disease MPN, might also harbor neoplastic mast cells [26].

Mastocytosis is frequently associated with somatic gain-of-function point mutations within *KIT*. *KIT* (CD117) is a Type III receptor tyrosine kinase that is expressed by MC, hematopoietic progenitor cells, germ cells, melanocytes, and interstitial cells of Cajal in the gastrointestinal tract

Additional Supporting Information may be found in the online version of this article.

¹Division of Hematology, Mayo Clinic, Rochester, Minnesota; ²Department of Medicine, Mayo Clinic, Rochester, Minnesota

Conflict of interest: Nothing to report

***Correspondence to:** Animesh Pardanani, MBBS, PhD, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. E-mail: pardanani.animesh@mayo.edu

Received for publication: 23 December 2014; **Accepted:** 24 December 2014

Am. J. Hematol. 90:251–262, 2015.

Published online: in Wiley Online Library (wileyonlinelibrary.com).

DOI: 10.1002/ajh.23931




Figure 1. Clinical spectrum of patients with clonal mast cell disorders. Please refer to Tables I and II for the WHO classification of mastocytosis. “Prediagnostic” SM refers to an abnormal clonal BM mast cell infiltrate that falls short of the diagnostic threshold for SM (generally satisfies 1–2 minor criteria only). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Diagnostic algorithm for systemic mastocytosis (SM)




Figure 2. Diagnostic algorithm for SM.

and is therefore functionally relevant for normal mast cell development, hematopoiesis, gametogenesis, melanogenesis, and regulation of slow gastric waves [27]. KIT expression is down regulated upon differentiation of hematopoietic progenitors into mature cells of all lineages, except mast cells, which retain high levels of cell surface KIT expression. The interaction between KIT and its ligand, stem cell factor, plays a key role in regulating mast cell proliferation, maturation, adhesion, chemotaxis, and survival [28].

Gain-of-function somatic mutations in the *KIT* tyrosine kinase domain, particularly the D816V mutation, have been found to occur

in a majority of cases of adult SM, irrespective of WHO SM subtype [9,29]. Other less common (<5%) somatic *KIT* mutations identified in adult SM include V560G [30,31], D815K [32], D816Y [29,32–34], insV1815–816 [29], D816F [32,34], D816H [35], and D820G [36]. Recent studies have confirmed that childhood-onset mastocytosis is also clearly clonal in nature, and is associated with germline or acquired activating *KIT* mutations [37–39]. In one study of pediatric CM that screened the entire *KIT* coding sequence for mutations using skin lesional DNA, only 42% of cases harbored missense mutations targeting *KIT*D816; in 44% of cases, genetic alterations (insertions

TABLE I. WHO Classification of Mastocytosis (adapted from Ref. [53])

1. CM:
 - (a). Urticaria pigmentosa (UP)/Maculopapular cutaneous mastocytosis (MPCM)
 - (b). Diffuse CM
 - (c). Solitary mastocytoma of skin
2. Indolent systemic mastocytosis (ISM)
 - Meets criteria for SM.^a No “C” findings.^a No evidence of associated clonal hematological non-mast cell lineage disease.
- (d). Smoldering systemic mastocytosis (SSM)^b
 - As above (ISM), but with 2 or more “B” findings, and no “C” findings.^a
- (e). Isolated BM mastocytosis^b
 - As above (ISM) with BM involvement, but without skin involvement.
3. SM with an associated clonal hematological nonmast cell lineage disease (SM-AHNMD)
 - Meets criteria for SM and criteria for AHNMD as a distinct entity per the WHO classification
4. Aggressive systemic mastocytosis (ASM)
 - Meets criteria for SM. One or more “C” findings.^a No evidence of MCL.
- (a) Lymphadenopathic mastocytosis with eosinophilia
5. MCL
 - Meets criteria for SM. BM biopsy shows a diffuse infiltration, usually compact, by atypical, immature mast cells. BM aspirate smears show $\geq 20\%$ mast cells. In typical MCL, mast cells account for $\geq 10\%$ of peripheral blood white cells. Rare variant: aleukemic MCL.
6. Mast cell sarcoma (MCS)
 - Unifocal mast cell tumor. No evidence of SM. Destructive growth pattern. High-grade cytology.
7. Extracutaneous mastocytoma
 - Unifocal mast cell tumor. No evidence of SM. No skin lesions. Nondestructive growth pattern. Low-grade cytology.

^a See Table II for diagnostic criteria for SM and definition of “B” and “C” findings.

^b Provisional categories.

(insFF419), deletions ($\Delta 419$), deletion-insertions ($\Delta 417-419insY$), internal tandem duplications (ITD SA501-502, ITD AY502-503, and ITD NFAF505-508) and missense mutations (D816V, D816Y, D816L, C443Y, S476I, K509I, D572A, and M541L) were found to mainly involve exons 8 and 9, which encode the fifth Ig (D5) domain and the extracellular region near the transmembrane domain. The aforementioned mutations in the exons 8 and 9 have been reported in CBF-AML ($\Delta 417-419insY$) [40,41], kindreds with familial GISTs and mastocytosis ($\Delta 419$) [42], familial mastocytosis (K509I) [43], and GISTs (ITD AY502-503) [44]. As with *KITD816V*, every one of the mutations in exons 8 and 9 that was tested was found to constitutively activate KIT kinase activity. Other rare germline *KIT* mutations that target the transmembrane domain and that are associated with familial mastocytosis include F522C and A533D [45,46].

While activating *KIT* mutations are frequently associated with human mastocytosis, they do not occur universally, and the question as to whether individual mutations are necessary and sufficient to cause mast cell transformation and whether such mutations alone explain the diverse clinical presentations of mastocytosis remains currently unsettled. Furthermore, while childhood- and adult-onset mastocytosis are both associated with activating *KIT* mutations, the natural history of the two conditions is quite different, with the former often exhibiting skin-limited disease that spontaneously regresses with age; in contrast, the latter is characterized by persistent multiorgan involvement, often with a concurrent non-MC hematologic neoplasm.

Experimental data with regard to this issue have not been conclusive; in transgenic mice expressing human *KITD816V* in mature MC (under the control of the chymase promoter), only a subset (30%) of

mice developed a limited form of mastocytosis (some with cutaneous-limited disease) at an old age (12–18 months) [47]. Although BM-derived MC from the transgenic animals eventually became growth factor independent and could be maintained in long-term cultures, the incomplete disease penetrance in this model suggested that additional somatic mutations are necessary for full MC transformation. In another transgenic mouse model that allowed conditional expression of murine *KITD814V* (the homolog of human *KITD816V*) driven by the *KIT* promoter, expression of mutant KIT in adult mice including in hematopoietic precursors caused severe mastocytosis with 100% penetrance at a young age [48]. Approximately half of the mice developed a non-MC lineage hematologic neoplasm, most frequently a leukemic disease derived from an immature B-cell precursor. The mice also developed a severe focal inflammatory colitis associated with a massive increase in mucosal mast cell numbers. In contrast, when mutant KIT expression in this model was limited to more mature MC, disease expression was significantly attenuated; while half of the mice developed MC tumors and erosive skin lesions and all developed severe colitis, the disease occurred significantly later and progressed much slower. While both the aforementioned transgenic murine models are imperfect (abnormal intracellular processing/trafficking of human *KITD816V* resulting in low oncogenicity in the former, and low transgene expression in the latter), they cumulatively suggest that the effects of constitutive KIT signaling depend on the developmental stage of the cell targeted by the gain-of-function mutation. As has been noted in mastocytosis patients [29], mutations targeting undifferentiated progenitors result in multilineage involvement and expression of a severe systemic disease phenotype; in contrast, mutations that target committed MC progenitors or mature MC result in milder forms of the disease.

Other oncogenic mutations recently identified in mastocytosis patients include those in *TET2* (*TET* oncogene family member 2) and *N-RAS* [49,50]. These mutations are not specific to mastocytosis and their pathogenetic role and/or prognostic impact is currently uncertain. *TET2* is a putative tumor suppressor gene; its mutational frequency in SM ranges from 20 to 29% [49,51]. *TET2* mutations cosegregate with *KITD816V* and functional cooperation between the two mutations appears to enhance oncogenicity of clonal MC; however, *TET2* mutations do not appear to independently impact survival in SM. Interestingly, expression of an activated M-RAS mutant (Q71L) in primary murine BM cells reproducibly generated a lethal mastocytosis and mast cell leukemia (MCL); in contrast, expression of constitutively activated H-RAS (G21V) produced a lethal histiocytic/monocytic leukemia, presumably reflecting significant differences in downstream signaling pathways in these disease models [52].

■ Diagnosis

The diagnosis and classification of mastocytosis is based on identification of neoplastic MC by morphological, immunophenotypic, and/or genetic (molecular) criteria using well established criteria as outlined by the 2008 WHO document (Tables I and II; Fig. 2) [1]. Biopsy of organs other than BM, such as liver or spleen, is infrequently pursued, either for diagnostic purposes or to demonstrate MC infiltration as the cause of impaired organ dysfunction. The diagnosis of SM in the absence of skin involvement is considerably more challenging, particularly in those patients with an indolent SM (ISM) variant with low mast cell burden, termed isolated BM mastocytosis (BMM) [53,54]; consequently, a high index of suspicion is required in the setting of recurrent unexplained anaphylaxis, flushing, osteoporosis, gastrointestinal ulcerative disease, or chronic abdominal cramping.

BM histology

In practice, the current diagnostic approach for SM starts with a BM examination since this site is almost universally involved in adult

TABLE II. WHO Diagnostic Criteria for SM (Adapted from Ref. [53])

The diagnosis of SM can be made when the major criterion and one minor criterion or at least three minor criteria are present

MAJOR CRITERION

Multifocal, dense infiltrates of mast cells (≥ 15 mast cells in aggregates) detected in sections of BM and/or other extracutaneous organs

MINOR CRITERIA

- a. In biopsy sections of BM or other extracutaneous organs, $>25\%$ of the mast cells in the infiltrate are spindle-shaped or have atypical morphology or, of all mast cells in BM aspirate smears, $>25\%$ are immature or atypical
- b. Detection of an activating point mutation at codon 816 of *KIT* in BM, blood or other extracutaneous organ
- c. Mast cells in BM, blood or other extracutaneous organ express CD2 and/or CD25 in addition to normal mast cell markers^a
- d. Serum total tryptase persistently exceeds 20 ng/mL (unless there is an associated clonal myeloid disorder, in which case this parameter is not valid)

“B” findings

1. BM biopsy showing $>30\%$ infiltration by MC (focal, dense aggregates) and/or serum total tryptase level >200 ng/mL
2. Signs of dysplasia or myeloproliferation, in non-MC lineage(s), but insufficient criteria for definitive diagnosis of a hematopoietic neoplasm (AHNMD), with normal or slightly abnormal blood counts.
3. Hepatomegaly without impairment of liver function, and/or palpable splenomegaly without hypersplenism, and/or lymphadenopathy on palpation or imaging.

“C” findings

1. BM dysfunction manifested by one or more cytopenia(s) (ANC $<1.0 \times 10^9/L$, Hgb <10 g/dL, or platelets $<100 \times 10^9/L$), but no obvious nonmast cell hematopoietic malignancy.
2. Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension.
3. Skeletal involvement with large osteolytic lesions and/or pathological fractures.
4. Palpable splenomegaly with hypersplenism.
5. Malabsorption with weight loss due to gastrointestinal mast cell infiltrates.

ANC indicates absolute neutrophil count; Hgb, hemoglobin; ng, nanograms; mL, milliliter; L, liter; and dL, deciliter.

^a Mast cell CD25 expression can be detected by flow cytometry or immunohistochemistry; the latter is probably more reliable and practical in most hematopathology laboratories, and may be the preferred methodology.

mastocytosis, and histological diagnostic criteria for non-BM, extracutaneous organ involvement in SM have not been firmly established or widely accepted as of yet. Further, BM examination also allows detection of a second hematologic neoplasm, if present [19,21].

In general, the pathognomonic multifocal dense MC aggregates, frequently in perivascular and/or paratrabecular BM locations (major diagnostic criterion), may not be readily recognized by standard dyes such as Giemsa, particularly when MC exhibit significant hypogranulation or abnormal nuclear morphology, or in cases with extensive BM involvement by a second hematological neoplasm (e.g., acute myeloid leukemia), or when significant reticulin fibrosis is present. Among the immunohistochemical markers, tryptase is the most sensitive, given that virtually all MC, irrespective of their stage of maturation, activation status, or tissue of localization express this marker, and consequently allows for detection of even small and/or immature MC infiltrates [55–57]. It must be emphasized however that neither tryptase nor KIT/CD117 immunostaining is able to distinguish between normal and neoplastic MC [58]. In addition, abnormal basophils seen in some cases of acute and chronic basophilic leukemia, as well as in chronic myeloid leukemia (CML), and blasts in some AML cases may be tryptase positive, and may prove difficult to distinguish from MC [19].

In contrast, immunohistochemical detection of aberrant CD25 expression on BM MC appears to be a reliable diagnostic tool in SM,

given its ability to detect abnormal MC in all SM subtypes, including the rare cases with a loosely scattered, interstitial pattern of MC involvement (see below) [57].

CD30 (Ki-1 antigen) has been reported to be preferentially expressed (proportion of cells as well as intensity of staining) in neoplastic MC from patients with aggressive SM (ASM) or MCL (11 of 13; 85%) as compared with ISM (12 of 45; 27%) [59]. In the latter group, CD30 expression was significantly correlated with serum tryptase level ≥ 50 ng/mL. An independent study of 142 SM patients confirmed aberrant CD30 expression (by flow cytometry) on neoplastic MC in a majority of subjects (80%); however, CD30 expression was similar across SM subgroups and there was no clear association between CD30 expression levels and specific clinicopathological characteristics [60]. The clinical implications of this finding are currently unclear given lack of independent confirmation of this relatively subjective assessment, small number of cases studied (particularly ASM/MCL), and overlap of CD30 expression between ISM and ASM/MCL (e.g., SSM cases were uniformly CD30-positive).

Mast cell immunophenotyping

Neoplastic MC generally express CD25 and/or CD2, and the abnormal expression of at least one of these two antigens counts as a minor criterion toward the diagnosis of SM per the WHO system [1]. Expression of CD2 on MC, as assessed by either flow cytometry or immunostaining, has been noted to be variable in SM, and consequently, CD25 expression may be more reliable marker for neoplastic MC [61,62]. The aforementioned immunostaining and immunophenotyping studies enhance the morphological and immunophenotypic distinction between normal (round and CD25-negative) and abnormal (spindle-shaped and CD25-positive) mast cells, respectively [56,62].

Serum tryptase level

Normal MC display a spectrum of “activation levels” in vivo, and the mechanisms governing the secretory phenotype and mediator release patterns are not completely understood [63]. In SM, an elevated serum tryptase level (>200 ng/mL) counts as a minor diagnostic criterion per the WHO framework [1]; while the levels vary widely, serum tryptase is elevated in the vast majority of SM patients across all WHO subgroups; a significantly greater proportion of ASM and SM-AHNMD patients exhibit a markedly elevated serum tryptase level (>200 ng/mL) compared to those with ISM [9]. Serum tryptase levels are also elevated in a significant proportion of cases with AML, CML, and MDS [64]; consequently, this test has limited diagnostic utility in the presence of a second SM-associated myeloid neoplasm. The correlation between MC mediator levels and presence of MC mediator-release symptoms (MCMRS) or systemic MC burden remains incompletely understood; in one study of indolent mastocytosis patients, MC mediator levels were significantly correlated with BM MC burden, but not MCMRS [54].

Molecular studies

Identification of *KIT*D816V counts as a minor diagnostic criterion per the WHO system [1]. Of note, there is a high correlation between *KIT* mutation detection and the proportion of lesional cells in the sample, as well as the sensitivity of the screening method employed [65]. Sensitivity of detection may be enhanced by enriching lesional MC by laser capture microdissection, or magnetic bead- or FACS-based cell sorting, respectively, [20,29,66] or through the use of highly sensitive PCR techniques [32]. Outside of a research setting, it is currently not standard practice to screen for *KIT* mutations other than those involving D816. The frequency of involvement of non-MC lineages (generally myeloid, but occasionally lymphoid lineages) by *KIT*D816V appears to be greater in cases of ASM or MCL, as compared with ISM [29]. In contrast, *KIT*D816V is variably present in cells representing the second hematological neoplasm in SM with




Figure 3. Algorithm for diagnostic assessment of patients presenting with systemic symptoms of mast cell degranulation, without skin involvement by mastocytosis (Reproduced from Ref. [53]).

associated clonal hematological non-mast cell lineage disease (SM-AHNMD) cases, depending upon the particular AHNMD subtype (CMML $>$ MPN, AML $>$ lymphoid neoplasms) [67].

Attempts at validating the WHO diagnostic criteria reveal that $\sim 20\%$ of ISM patients lack mast cell clusters in the BM and $\sim 30\%$ exhibit a serum tryptase level lower than 20 ng/mL [68]. In contrast, the sensitivity for detecting morphologic atypia, aberrant CD25 and/or CD2 expression, or *KITD816V* in BM mast cells exceeds 90% when sensitive assays are used, thereby illustrating the increasing importance of these specific minor criteria in diagnosing SM [68,69]. Patients who have mast cell degranulation symptoms with clonal mast cells (i.e., mutated *KIT* gene and/or CD25 expression), but who do not meet criteria for SM (only 1 or 2 minor criteria satisfied, and no skin involvement), may have “pre-diagnostic ISM” or “monoclonal mast cell activation syndrome” (Fig. 3); these patients generally have normal or slightly elevated baseline serum tryptase level [70]. While the clinical characteristics of this entity may be indistinguishable from ISM, its true natural history remains to be defined.

Rare SM cases may exhibit a well-differentiated phenotype (i.e., relatively normal BM MC morphology; absence of aberrant MC CD25/CD2 expression); these cases are associated with non-D816V *KIT* mutations (e.g., germline F522C or somatic I817V) and, in the case of *KITF522C*-associated SM, has been shown to be sensitive to imatinib therapy [29,45].

In the presence of blood eosinophilia, screening for *FIP1L1-PDGFRα*, using either FISH or RT-PCR, is warranted [16]. In contrast, conventional cytogenetics analysis generally permits identification of cases of BMM associated with a *PDGFRB* rearrangement (i.e., chromosomal translocations involving 5q31-32) [18]. These cases with *PDGFRα/PDGFRB*-rearranged MPN with BM MC hyperplasia are appropriately classified as “Myeloid or lymphoid neoplasms with eosinophilia and abnormalities of *PDGFRα*, *PDGFRB*, or *FGFR1*” per the WHO classification [10].

■ Risk Stratification

This section focuses on adult SM patients; their life expectancy, when considered as a group, appears to be shorter as compared to

age- and gender-matched controls, with the excess deaths in this group occurring within the first 3–5 years after diagnosis (Fig. 4A) [9,71].

The categorization of adult SM patients per the 2008 WHO classification system remains the most practical first step in risk stratifying newly diagnosed patients [1]. The WHO classification recognizes seven mastocytosis categories (Table I) SM is subclassified into four subcategories: ISM (no evidence of extracutaneous organ dysfunction), ASM (presence of extracutaneous organ dysfunction), SM associated with another clonal hematological non-MC lineage disease (SM-AHNMD), and MCL.

A recent study of 342 adult patients has validated the prognostic value of the WHO classification for SM [9].

Indolent SM

It comprised the largest subgroup ($n = 159$; 46%) [9]. Compared with patients with ASM and SM-AHNMD, ISM patients were significantly younger at presentation (median age 49 years) and had a higher prevalence (66–75%) of UP-like skin lesions, MCMRS and gastrointestinal symptoms; ISM patients were significantly less likely however to exhibit constitutional symptoms or hepatosplenomegaly ($<20\%$).

The WHO system recognizes two provisional ISM subvariants: smoldering SM (SSM) and isolated BMM [1]. SSM is characterized by a higher burden of MC defined by the presence of ≥ 2 “B-findings” (Tables I and II; Fig. 2). Of the 159 ISM patients in the aforementioned series, 22 (14%) had SSM, 36 (23%) BMM, and the remaining 101 (63%) did not fit in with either category (ISM-other) [54]. SSM patients were significantly older (median age 64 years) than patients with BMM or ISM-other and more frequently presented with constitutional symptoms (45%), anemia (55%) and elevated MC mediator levels. In contrast, BMM patients more frequently presented with MCMRS (86%), including anaphylaxis (78%). Overall median survival in ISM was 198 months, which was not significantly different than that of the age- and sex-matched U.S. control population (Fig. 4B, red curve). SSM patients had a significantly inferior survival (median 120 months) as compared to those with ISM-other (median 301 months) or BMM (not reached).




Figure 4. (a) The observed Kaplan-Meier survival for SM patients (red) compared with the expected age and gender matched US population's survival (blue). (b) The observed Kaplan-Meier survival for SM patients classified by disease type ISM (red), ASM (green), AHNMD (yellow), and MCL (purple) compared with the expected age and gender matched US population's survival (blue) for the entire cohort. (Reproduced from Ref. [9]). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

In a multivariable analysis, advanced age was the primary determinant of inferior survival and accounted for the marked difference in survival between SSM and the other two groups. The overall risk of transformation to acute leukemia or ASM was low (<1 and 3%, respectively) but was significantly higher in SSM (18%). Another recent study confirmed the low-rate of disease progression in ISM; after a median follow up of 147 months (range 61–329), the progression rate was 3%; predictors of disease progression were serum β 2-microglobulin level and multilineage presence of *KITD816V* [72].

SM with associated clonal hematological nonmast cell lineage disease

SM-AHNMD was the second most common SM subgroup ($n = 138$; 40%) in the aforementioned series [9,22]. Of these, 123 (89%) had an associated myeloid neoplasm, while the remainder had lymphoma ($n = 7$), myeloma ($n = 5$), chronic lymphocytic leukemia ($n = 2$), or primary amyloidosis ($n = 1$). Of the patients with an associated myeloid malignancy, 55 (45%) had SM-MPN, 36 (29%) SM-chronic myelomonocytic leukemia (SM-CMML) and 28 (23%) SM-MDS. A significant proportion ($n = 42$; 34%) exhibited prominent eosinophilia ($\geq 1.5 \times 10^9/L$), especially those with SM-MPN ($n = 31$; 56%); of the latter, 12 (39%) harbored the *FIP1L1-PDGFR* fusion.

Overall median survival in SM-AHNMD was 24 months (Fig. 4B, gold curve). SM-MPN patients had a significantly longer median survival (31 months) as compared with patients with SM-CMML

(15 months), SM-MDS (13 months), or SM-AL (11 months). Leukemic transformation (13% overall) was seen significantly more frequently in SM-MDS (29%), as compared with SM-MPN (11%) or SM-CMML (6%). Clinical outcome was similar between SM-MPN patients with or without eosinophilia.

Aggressive SM

ASM was the third most common subgroup ($n = 41$; 12%) in the aforementioned series [9]. ASM patients frequently displayed constitutional symptoms (60%), hepatosplenomegaly (50%), lymphadenopathy (30%), severe anemia (Hgb <10 g/dL; 24%), or thrombocytopenia (platelets $<100 \times 10^9/L$; 27%), leukocytosis (41%), and markedly elevated serum tryptase levels (>200 ng/mL; 40%). Overall median survival in ASM was 41 months (Fig. 4B, green curve) and leukemic transformation occurred in 2 patients (5%).

Mast cell leukemia

MCL was relatively rare ($n = 4$; 1%) in the aforementioned series [9]; the prognosis in these cases was dismal with median survival of only 2 months (Fig. 4B, violet curve).

In addition to WHO SM subtype, multivariable analysis shown a significant and independent association between inferior survival and advanced age ($P < 0.0001$), history of weight loss ($P = 0.01$), anemia ($P = 0.007$), thrombocytopenia ($P = 0.0008$), hypoalbuminemia ($P = 0.0008$), and excess BM blasts ($>5\%$; $P = 0.004$) [9].

A recent study showed increased plasma IL-2R α /CD25 levels to be associated with inferior overall survival in advanced and ISM patients, independent of conventional risk factors [73].

KITD816V, which is the hallmark of adult SM, has been shown to occur in BM hematopoietic cell compartments other than MC, particularly in cases of SM-AHNMD, ASM, and MCL, but less frequently in ISM, thereby indicating involvement of a pluripotent stem cell in such cases [29]. Further, comprehensive immunophenotyping has shown that an immature BM MC phenotype (CD25⁺/Fc ϵ R1^{lo}/FSC^{lo}/SSC^{lo}/CD45^{lo}), in the absence of coexisting normal MC in the BM, correlated with multilineage hematopoietic involvement by *KITD816V*, regardless of the WHO SM subtype [74]. In contrast, BM MC from patients with ISM subtypes displayed a mature activated MC phenotype (e.g., increased expression of MC activation markers CD63, CD69, and CD203c in patients with BMM) [75]. While such assays require considerable technical expertise, and consequently are not routinely available, these data indicate the prognostic value of the aforementioned observations; in one study, multilineage *KITD816V* involvement was the most important prognostic criterion for progression of ISM to more ASM subtypes [72].

Treatment

While treatment of adult SM is highly individualized, it is guided only to a limited extent by the presence or absence of a particular molecular abnormality. In general, treatment with small-molecule kinase inhibitors has yielded only modest clinical benefits, likely due to yet unrecognized complexities in the molecular pathogenesis of SM, redundancies in cellular signaling pathways and/or ineffectiveness of currently available in vivo *KITD816V*-inhibitors. For the rare SM patient with a transmembrane KIT mutation (e.g., F522C or K509I), dramatic clinical responses to imatinib therapy can be observed [43,45]. Overall however, although progress has been achieved with some of the newer investigational agents (e.g., midostaurin/PKC412), the promise of truly “targeted therapy” in the vast majority of SM patients (akin to imatinib therapy in CML) has yet to be realized. Drug therapy has not been shown to favorably affect survival in SM and the experience with allogeneic stem cell transplantation remains limited [76,77]. Current therapy in WHO-defined SM is largely

TABLE III. Pharmacologic Therapies for Symptom Control in Adult Patients with ISM (Adapted from Ref.[53]).

Symptoms	Treatment ladder ^b	Drug class	Specific drugs/doses	Common side effects (>5-10%)/Precautions ^c
Pruritus/flushing	First-line	H1-antagonist	Cetirizine 5-10 mg/d* Fexofenadine 60 mg BID or 180 mg/d* Hydroxyzine 25mg q 6 h* *Doses can be increased with supervision if indicated	Headache, somnolence, confusion, asthenia, xerostomia Precautions: Hydroxyzine -anticholinergic effects: use with caution in older patients, those with glaucoma, BPH, asthma, etc.
	Second-line	Leukotriene antagonist	Montelukast 10 mg/d Zafirlukast 20 mg BID	Headache Precautions: liver function impairment, neuropsychiatric conditions
	Third-line	Nonsteroidal anti-inflammatory drug	Aspirin (see text)	Gastrointestinal bleeding, peptic ulcer disease Precautions: may precipitate anaphylactic reaction (see text), aspirin hypersensitivity, children/adolescents with flu (Reye's syndrome), hepatic or renal dysfunction, bleeding disorders
	Third-line	Psolaren plus ultraviolet A (PUVA) photochemotherapy	See specialized texts	Nausea, pruritus, erythema of varying degree, increased risk of nonmelanoma skin cancers Contraindications: Pregnancy, xeroderma pigmentosa, lupus erythematosus with photosensitivity
Abdominal pain, cramping, diarrhea, heartburn, nausea, vomiting	First-line	H2-antagonist	Ranitidine 150 mg BID Famotidine 10 mg BID Cimetidine 400 mg BID	Headache, abdominal pain, dizziness, constipation, diarrhea Cimetidine: gynecomastia
	Second-line	Proton pump inhibitor	Omeprazole 20 mg/d Pantoprazole 40 mg/d Rabeprazole 20 mg/d	Headache, abdominal pain, nausea, vomiting, diarrhea, flatulence
	Third-line	Sodium cromolyn	100-200 mg QID 30 min before meals and bedtime	Dysgeusia, cough, osmotic diarrhea
	Fourth-line	Corticosteroid	Prednisone 0.5-1 mg/kg/d starting dose; taper as feasible based on response/tolerance	Dose/duration dependent (consult comprehensive drug reference resource)
Headache, cognitive impairment, depression	First-line	H1- and H2-antagonist	As above	As above
	Second-line	Sodium cromolyn	As above	As above
Recurrent hypotension ^a	First-line	Epinephrine	See text	See text
	Second-line	H1- and H2-antagonists	As above	As above
	Third-line	Corticosteroid	Prednisone (as above)	As above
	Fourth-line	Cytoreductive therapy (Interferon- α or 2-chlorodeoxyadenosine)	See text/below	See text/below
Osteoporosis	First-line	Bisphosphonate	Alendronate 70 mg q week Risedronate 35 mg q week Pamidronic acid 90 mg IV q 4 weeks	Flu-like symptoms, abdominal pain, nausea, vomiting, diarrhea, asthenia, hypocalcemia, rash musculoskeletal pain, headache, osteonecrosis of the jaw, nephrotoxicity. Follow established guidelines for bisphosphonate use (see text)
			Zoledronic acid 4 mg IV q 4 weeks	Precautions: esophageal/upper GI disease (oral bisphosphonates), renal disease, poor oral hygiene, or dental procedures
	Second-line	Cytokine/Immunomodulatory drug	Interferon- α Starting dose: 1-3 MU SQ three times per week Target dose: 3-5 MU SQ 3-5 times per week	Dose dependent (consult comprehensive drug reference resource) Comment: pegylated interferon may be better tolerated
Third-line	Purine nucleoside analogue	2-Chlorodeoxyadenosine (Cladribine/2-CdA) Dose: 5mg/m ² IV \times 5 days every 4-8 weeks	Myelosuppression, immunosuppression	

^a Avoidance of symptom trigger(s) applies to all patients. Those at risk of anaphylaxis should carry an emergency kit with self-injected epinephrine (EpiPen) (see text). Immunotherapy can be considered in those with IgE-mediated allergic reactions (see text).

^b Treatments can be combined in a stepwise manner for inadequate symptom control at prior step if clinically indicated/feasible.

^c Basic overview provided. Consult a comprehensive drug reference manual for detailed information regarding feasibility of use during pregnancy, black box warnings, specific contraindications/precautions, drug-drug interactions, dose reduction for hepatic/renal dysfunction, etc.

H1- and H2- indicate histamine receptor 1 and 2, respectively; mg, milligram; d, day; QD, once daily; BID, twice a day; QID, four times a day; BPH, benign prostatic hypertrophy; kg, kilogram; q, every; MU, million units; GI, gastrointestinal; SQ, subcutaneously; and IV, intravenously.

palliative and directed at MC degranulation symptoms (e.g., pruritus, urticaria, angioedema, flushing, nausea, vomiting, abdominal pain, diarrhea, episodic anaphylactoid attacks; Table III), symptomatic skin disease (e.g., urticaria pigmentosa) and/or organ dysfunction from MC tissue infiltration (e.g., hypersplenism or pathologic fracture). Treatment options in SM range from observation alone (supplemented by preventative measures to avoid precipitating MCMRS), to symptom management (e.g., managing pruritus or diarrhea), to supportive measures (e.g., red blood cell transfusion or osteoporosis treatment), to cytoreductive therapy for MC debulking in the setting of aggressive, advanced, or treatment-refractory disease. Results from a retrospective study of SM patients who underwent allogeneic stem cell transplantation (ASCT) were recently reported; of a total 57 patients (median age 46 years), 38 had SM-AHNMD (20 with AML), 12 MCL, and 7 ASM [77]. The primary assessment of treatment response was at day +100 post-ASCT; 16 patients (28%) achieved complete remission of the mastocytosis component with 2 patients becoming *KITD816V*-negative. Another 24 (42%) and 12 patients (21%) had partial response and stable disease, respectively; primary refractoriness was chiefly observed in MCL patients. The associated hematological malignancy was more treatment sensitive, with complete remission of this component being noted in all 38 SM-AHNMD patients. Overall survival at 3 years was 55% for the entire cohort, and 74% for the SM-AHNMD subgroup. Predictors of poor overall survival were presence of MCL (versus ASM or SM-AHNMD), reduced-intensity (versus myeloablative) conditioning and disease-progression (versus response or stable disease). Recently published consensus criteria will facilitate objective and standardized assessment of treatment response in patients with advanced SM in the era of novel, molecularly targeted drugs [78].

Currently used agents for SM therapy are presented below. Our current algorithm for SM treatment is illustrated in Fig. 5.

Interferon (IFN)- α

IFN- α is often considered the first-line cytoreductive therapy in symptomatic SM; since the initial report in 1992 [79], several case reports or small series have shown IFN- α (IFN- α 2b in most instances) to improve symptoms of MC degranulation, decrease BM MC infiltration, and ameliorate mastocytosis-related ascites/hepatosplenomegaly, cytopenias, skin findings, and osteoporosis [80–92]. IFN- α treatment is not uniformly effective [93], and the frequency of major response (i.e., complete resolution of one or more baseline ‘C’ findings) is ~20–30%; the optimal dose and duration of IFN- α therapy for SM remain unclear, however concurrent administration of corticosteroids (prednisone) may improve its efficacy (up to 40% major response rate) and tolerability [87,94]. The time to best response may be a year or longer [87] and delayed responses to therapy have been described [95]. IFN- α treatment is frequently (up to 50%) complicated by toxicities, including flu-like symptoms, bone pain, fever, cytopenias, depression, and hypothyroidism; consequently, the adverse dropout rate with IFN- α treatment is not trivial [87,96,97]. Finally, a significant proportion of patients will relapse within a short period of IFN- α treatment being discontinued, illustrating the cytostatic rather than cytolytic effects of the drug [97].

In a French study, 20 SM patients (16 ASM and 4 ISM) were treated with IFN- α starting at 1 MU/day with progressive increase to 5 MU/m²/day; 13 patients were treated for at least 6 months (median dose 3.2 MU/day) [97]. All 13 patients exhibited responses (non were complete) in systemic and cutaneous disease manifestations that were associated with decrease in circulating MC mediator levels, but not in BM MC burden. Adverse effects were frequent (cytopenias and depression in 9 and 7 patients, respectively); there were two deaths during the treatment phase. Four responding patients experienced prompt relapse of symptoms after treatment cessation.

In the Mayo Clinic study, 47 patients received IFN- α with or without prednisone [96]; the median weekly dose was 15 MU per week (range 3.5–30 MU per week) and the initial dose of prednisone ranged from 20 to 60 mg per day with a slow tapering over weeks or months in some patients. In 40 evaluable patients, the overall response rate (ORR) was 53% (ISM and ASM 60%; SM-AHNMD 45%). Overall median duration of response was 12 months (range 1–67 months). Responses were not significantly different when comparing patients who did and did not receive prednisone. Absence of systemic mediator-related symptoms was significantly associated with inferior response to IFN- α ; 41 vs. 77%, respectively. Major toxicities included fatigue, depression, and thrombocytopenia.

Summary. IFN- α has activity in all SM subcategories and has been shown to improve dermatological, hematological, gastrointestinal, and systemic symptoms associated with histamine release. IFN- α also has a role in treating skeletal symptoms because of its ability to increase bone density. Use of higher doses of IFN- α has the potential to decrease the BM MC burden in some patients. We commonly start treatment at the dose of 1–3 million units (MU) subcutaneously three times per week, followed by gradual escalation to 3–5 MU three to five times per week, if tolerated. Prednisone (30–60 mg/day) is commonly added at the start of treatment to improve tolerability and response, and is tapered over a 2–3 month period. IFN- α treatment is generally continued as long as a response is observed and there are no intolerable adverse effects.

2-Chlorodeoxyadenosine (cladribine or 2-CdA)


Has demonstrated *in vitro* and *in vivo* activity against neoplastic MC; the published experience suggests that 2-CdA has therapeutic activity in all SM subtypes including in MCL [98–103].

In the Mayo Clinic study, 2-CdA was administered to 26 patients (8 as first-line); the dose was 5 mg/m² per day or 0.13–0.17 mg/kg per day for 5 days as a 2-h intravenous (IV) infusion, and median number of treatment cycles was 3 (range 1–9) [96]. Treatment response was evaluable in 22 patients and the ORR was 55% (ORR in ISM, ASM, and SM-AHNMD was 56, 50, and 55%, respectively). Median duration of response was 11 months (range 3–74 months). Presence of circulating immature myeloid cells was significantly associated with inferior response to 2-CdA (0 vs. 75%). Major toxicities were myelosuppression and infection.

In a recent French study, 44 patients with mastocytosis were treated with 2-CdA (CM = 3, ISM = 19, SSM = 3, ASM = 12, SM-AHNMD = 6, and MCL = 1) [104]. All patients had failed previous symptomatic therapy and/or IFN- α (n = 10) or kinase inhibitors (n = 7). 2-CdA was given at 0.15 mg/kg/day in a 2-h infusion or subcutaneously for 5 days, repeated every 1–2 months, for a median of four cycles. After a median follow up of 35 months, no opportunistic infections were seen with the exception of zoster infection in two patients. Responses occurred in 24/31 patients with urticaria pigmentosa, 17/35 with fatigue, 14/24 with flushing, 9/24 with pruritus, 9/21 with abdominal pain, 1/9 with ascites, 11/23 with diarrhea, 8/16 with weight loss, 4/14 with headache, 5/10 with cough, 7/20 with splenomegaly, 2/6 with lymphadenopathy, 0/2 with pleural effusions, and 5/19 with neuropsychological symptoms. In addition, eosinophil count normalized in 7/10 cases and a substantial decrease in tryptase levels was also noted. Overall, major (MR) and partial (PR) responses were observed in 7/12 patients with ASM, 3/3 SSM, 17/19 ISM, 2/3 CM but in none of the patients with SM-AHNMD. Median duration of response was ~20 months.

Summary. 2-CdA has activity in all SM subtypes. We use 2-CdA as first-line treatment in cases where rapid MC debulking is indicated, or in symptomatic patients who are refractory or intolerant to IFN- α . Potential toxicities of 2-CdA include myelosuppression and lymphopenia with increased risk of opportunistic infections. The

Treatment algorithm for systemic mastocytosis (SM)



^{††} *FIP1L1-PDGFR*A positive, reclassify as "Myeloid neoplasm with eosinophilia and abnormalities of *PDGFR*A, *PDGFR*B, or *FGFR*"

Figure 5. Algorithm for the treatment of SM.

limited activity of 2-CdA in SM-AHNMD patients noted in the French study is discrepant with published data; the discrepancy may relate to alternative interpretation of the treatment response data and needs to be confirmed.

Imatinib mesylate (IM)

Demonstrates in vitro efficacy against wild-type KIT and certain transmembrane (F522C) and juxta-membrane (V560G) KIT mutants, but not the common kinase (D816V) domain mutants [45,105–107]. Similarly, not all juxta-membrane mutations may be sensitive to IM (e.g., V559I) [108].

In the Mayo Clinic study that excluded *FIP1L1-PDGFR*A-positive cases, IM was administered to 27 SM patients; the median starting dose was 400 mg per day (range 100–400 mg/day), and the maintenance dose in responding patients ranged from 200 to 400 mg/day [96]. In 22 evaluable patients, the ORR was 18% (ORR in ISM, ASM, and SM-AHNMD was 14, 50, and 9%, respectively), and median duration of response was 19.6 months (range 9–69 months). Responses included improvement in UP and decrease in the BM MC burden. The majority (86%) of IM treated patients were *KITD816V* positive—ORR in mutation-positive and—negative patients was 17 and 33%, respectively. None of the six patients with SM and associated eosinophilia (all *KITD816V*-positive) responded to IM treatment. Major toxicities included diarrhea and peripheral edema; two patients developed interstitial pneumonitis.

Data from another study however suggested an ORR of 36% in *KITD816V*-positive SM patients [109]. In yet another study of 20 SM patients treated with IM, only one *KITD816V*-negative patient responded while six other patients reported symptomatic improvement [110]. Finally, in another study wherein 17 SM patients received IM treatment, the response rate was 29% (one complete and four partial remissions), all in *KITD816V*-negative patients [111].

Summary. While IM is the only SM treatment currently approved by the Food and Drug Administration (FDA) (specific indication is treatment of adult patients with ASM without the *KITD816V* mutation or with unknown KIT mutational status), it has a limited role in

the treatment of unselected SM patients, the majority of whom likely harbor *KITD816V*. The rare SM cases that harbor an IM-sensitive KIT mutation, or those that are *KITD816V*-unmutated may be appropriate candidates for IM treatment.

Hydroxyurea (HU)

In the Mayo Clinic study, HU was given to 30 SM patients (28 with SM-AHNMD) [96]. The drug was used as first-line therapy in 24 patients. The dose ranged from 500 mg every other day to 2000 mg per day. Treatment response was evaluable in 26 patients; control of thrombocytosis, leukocytosis and/or hepatosplenomegaly was observed in 5 SM-AHNMD patients (ORR = 19%). Median duration of response was 31.5 months (range 5–50 months) and the major toxicity was myelosuppression.

Summary. The utility of HU in treating SM-AHNMD stems from its myelosuppressive activity. HU does not however exhibit any substantial anti-MC effect.

Investigational agents:

1) Dasatinib has shown efficacy in vitro against various KIT mutants including *D816V* [112,113]. Furthermore, dasatinib may synergize with PKC412 and chemotherapy in this regard [114–116]. In the largest study of dasatinib therapy in SM [117], the drug was given at a starting dose of 70 mg PO bid to 33 SM patients: 18 ISM, 9 ASM, and 6 with SM-AHNMD. Two (6%) patients, both of whom were *D816V*-negative, achieved complete remission. Nine (27%) patients experienced symptomatic improvement. Grade 3 toxicities were observed in 19 (58%) patients. In another report [118], 4 SM patients (all *KITD816V* positive; 2 with ASM, 1 SM-AHNMD, and 1 ISM) were treated with dasatinib at a dose ranging from 50 to 100 mg twice daily. Two patients (one each with ASM and SM-AHNMD) had a major response, which in the case of the SM-AHNMD patient was accompanied by decrease in the BM MC burden. Both responders experienced an initial exacerbation of MCMRS and rash lasting several days before the benefits of dasatinib therapy became evident.

Summary. Dasatinib appears to have modest activity in KITD816V-positive SM. The cumulative published experience to date does not clarify as to which group of SM patients is likely to obtain the most benefit from dasatinib therapy.

2) Midostaurin (PKC412) has *in vitro* activity against kinase domain KIT mutants (D816Y and D816V) [99,119], and treatment of a patient with MCL who harbored *KITD816V* resulted in transient clinical benefit [120]. In the global Phase 2 CPKC412D2201 trial, 116 patients with advanced SM were enrolled; the efficacy population comprised of 89 patients (73 with ASM, of which 57 had an associated hematological malignancy, and 16 with MCL); patients were treated with PKC412 at 100 mg BID [121]. Major response rate per conventional criteria was 45%; another 15% had partial response and 12% stable disease. Major responses included normalization of hypoalbuminemia (58%), improvement of hemoglobin (33%) and platelet counts (40%), resolution of liver function abnormalities (~50%), and reversion of weight loss (25%). Patients reported improvement of disease-related symptoms with treatment. After a median follow up of 26 months (range 12–54 months), the median response duration for the overall efficacy population, ASM and MCL subgroups was 24 months, 24 months and not reached, respectively. The corresponding median overall survival for the the 3 groups was 29, 34, and 9 months, respectively. Approximately a third of patients had $\geq 50\%$ decrease in BM mast cell burden on two consecutive biopsies and $\geq 50\%$ decrease in serum tryptase level during two consecutive cycles as compared to baseline. Of the 116 patients, 72% had discontinued treatment (up to 30% due to adverse events). The most common drug side effects were nausea, vomiting, diarrhea, and fatigue; treatment-related cytopenias were also observed.

Summary. PKC412 has activity in SM and might produce substantial reduction in MC burden in some patients. However, it is currently not clear which patients with SM stand to benefit from such treatment and more studies are needed to clarify the advantage of PKC412 over treatment with IFN- α or cladribine, which are currently considered first line treatment in ASM or symptomatic ISM.

3) Masatinib mesilate (AB1010) has been shown to inhibit human and murine KIT with juxtamembrane activating KIT mutations, as well as PDGFRA- α/β , and Lyn kinases at nanomolar concentrations in cell-based assays [122]. In contrast, masatinib only

weakly inhibited KITD816V-driven cell proliferation (micromolar concentrations). Masatinib was administered to 25 patients with symptomatic cutaneous or ISM that was refractory to conventional therapy, and where *KITD816V* was absent in at least one MC infiltrated organ (skin or BM) [123]. Patients were randomized to receive 3 or 6 mg/kg/day for 12 weeks; the primary endpoint was change in symptoms at week 12 relative to baseline. There was a significant improvement in frequency of flushing, pruritus score, and Hamilton rating for depression by 64, 36, and 43%, respectively. The overall clinical response ($\geq 50\%$ improvement in baseline symptom without deterioration or emergence of another symptom) was 56%. Twenty-two patients (88%) completed the study; two discontinued due to adverse events (AE). In the initial 12 week phase, 21 patients (84%) experienced at least one masatinib-related AE (mild [$n = 11$], moderate [$n = 19$] and severe [$n = 9$]). The most common AE were nausea/vomiting (52%), edema (44%), muscle spasms (28%) and rash (28%). One patient developed masatinib-related agranulocytosis that was reversible. Seventeen patients (68%) entered the extension phase and at the time of publication, 8 patients (32%) were still receiving treatment. In another report of 35 ISM patients (22 and 2 patients with mild-moderate and severe depression, respectively), depression scores were significantly improved (20% improvement in initial score) in 67% of cases after masatinib therapy for 12 weeks [124].

Summary. Given its lack of activity against *KITD816V*, masatinib appears to be at a disadvantage as compared to other “targeted” therapies for the treatment of adult SM. In the absence of a head-to-head trial, it is unclear if masatinib has any clear advantage over imatinib for the treatment of symptomatic ISM. The frequency of AE in the former study was relatively high, which likely explains why the QLQ-C30 symptom score showed little improvement as compared with baseline.

4) Brentuximab vedotin is an antibody-drug conjugate directed against the cell-membrane protein CD30, which a member of the tumor necrosis factor receptor superfamily. Given the reported aberrant expression of CD30 on neoplastic MC, with preferential expression in advanced SM as compared to ISM (see above) [59], the role of brentuximab vedotin in treating advanced SM including MCL is being currently studied (Clinicaltrials.gov study# NCT01807598).

References

- Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: International Agency for Research and Cancer (IARC); 2008. pp 54–63.
- Brunning RD, McKenna RW, Rosai J, et al. Systemic mastocytosis. Extracutaneous manifestations. *Am J Surg Pathol* 1983;7:425–438.
- Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. *Hum Pathol* 1985;16:808–814.
- Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. *Am J Clin Pathol* 2001;116:177–182.
- Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. *Arch Dermatol* 1963;87:146–157.
- Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology. *Pediatr Blood Cancer* 2009;53:629–634.
- Azana JM, Torrello A, Mediero IG, et al. Urticaria pigmentosa: A review of 67 pediatric cases. *Pediatr Dermatol* 1994;11:102–106.
- Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. *Ann Allergy* 1994;73:197–202; quiz 202–197.
- Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. *Blood* 2009;113:5727–5736.
- Bain BJ, Gilliland DG, Horny HP, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: International Agency for Research and Cancer (IARC); 2008. pp 68–73.
- Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;348:1201–1214.
- Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. *Blood* 2003;101:4660–4666.
- Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. *Blood* 2004;103:473–478.
- Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFR fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood* 2004;104:3038–3045.
- Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. *Lancet* 2003;362:535–536.
- Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFR fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood* 2003;102:3093–3096.
- Dalal BI, Horsman DE, Bruyere H, et al. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation. *Am J Hematol* 2007;82:77–79.
- Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. *Haematologica* 2007;92:163–169.
- Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage diseases: A histopathological challenge. *J Clin Pathol* 2004;57:604–608.
- Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816 \rightarrow val in micro-dissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. *Leuk Res* 2002;26:979–984.
- Travis WD, Li CY, Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. *Cancer* 1988;62:965–972.

22. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. *Blood* 2009;114:3769–3772.
23. Pardanani A, Reeder T, Li CY, et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. *Leuk Res* 2003;27:883–885.
24. Taylor ML, Sehgal D, Raffeld M, et al. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. *J Mol Diagn* 2004;6:335–342.
25. Tefferi A, Lasho TL, Brockman SR, et al. FIP1L1-PDGFR α and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. *Haematologica* 2004;89:871–873.
26. Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. *Arch Pathol Lab Med* 2005;129:219–222.
27. Miettinen M, Lasota J. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. *Appl Immunohistochem Mol Morphol* 2005;13:205–220.
28. Valent P, Spanbloch E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kilid ligand in long-term culture. *Blood* 1992;80:2237–2245.
29. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. *Blood* 2006;108:2366–2372.
30. Buttner C, Henz BM, Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. *J Invest Dermatol* 1998;111:1227–1231.
31. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. *J Clin Invest* 1993;92:1736–1744.
32. Sotlar K, Escobedo L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. *Am J Pathol* 2003;162:737–746.
33. Beghini A, Cairoli R, Morra E, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. *Blood Cells Mol Dis* 1998;24:262–270.
34. Longley BJJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. *Proc Natl Acad Sci USA* 1999;96:1609–1614.
35. Pullarkat VA, Pullarkat ST, Calverley DC, et al. Mast cell disease associated with acute myeloid leukemia: Detection of a new c-kit mutation Asp816His. *Am J Hematol* 2000;65:307–309.
36. Pignoni JM, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. *Br J Haematol* 1997;96:374–376.
37. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. *J Invest Dermatol* 2010;130:804–815.
38. Yanagihori H, Oyama N, Nakamura K, et al. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. *J Mol Diagn* 2005;7:252–257.
39. Verzijl A, Heide R, Oranje AP, et al. C-kit Asp816-val mutation analysis in patients with mastocytosis. *Dermatology* 2007; 214:15–20.
40. Gari M, Goodeve A, Wilson G, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. *Br J Haematol* 1999;105:894–900.
41. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia* 2005;19:1536–1542.
42. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. *Gastroenterology* 2005;129:1042–1046.
43. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. *Leuk Res* 2006;30:373–378.
44. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. *Am J Pathol* 2000;156:791–795.
45. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. *Blood* 2004;103:3222–3225.
46. Tang X, Boxer M, Drummond A, et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. *J Med Genet* 2004;41:e88.
47. Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human kit receptor with the activating Asp816Val mutation. *J Exp Med* 2005;202:1635–1641.
48. Gerbaulet A, Wickenhauser C, Scholten J, et al. Mast cell hyperplasia, B cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. *Blood* 2011;117:2012–2021.
49. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFR α correlates. *Leukemia* 2009;23:900–904.
50. Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. *Haematologica* 2011;96:459–463.
51. Soucie E, Hanssens K, Mercher T, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. *Blood* 2012;120:4846–4849.
52. Guo X, Schrader KA, Xu Y, et al. Expression of a constitutively active mutant of M-ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-ras. *Oncogene* 2005;24:2330–2342.
53. Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). *Blood*, 2013;121:3085–3094.
54. Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults. *Blood* 2010;115:150–151.
55. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. *Am J Surg Pathol* 1998;22:1132–1140.
56. Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. *Int Arch Allergy Immunol* 2002;127:115–117.
57. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. *Am J Surg Pathol* 2004;28:1319–1325.
58. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/kit, and bcl-x(L). *Hum Pathol* 2001;32:545–552.
59. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. *Mod Pathol* 2011;24:585–595.
60. Morgado JM, Perbellini O, Johnson RC, et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. *Histopathology* 2013;63:780–787.
61. Escobedo L, Garcia-Montero AC, Nunez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: Role in diagnosis and follow-up of mast cell disease. *Immunol Allergy Clin North Am* 2006;26:535–547.
62. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients. *Leuk Res* 2004;28:777–783.
63. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. *Annu Rev Immunol* 2005;23:749–786.
64. Sperr WR, El-Samahy A, Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology. *Eur J Clin Invest* 2009;39:914–923.
65. Akin C. Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital symposium on molecular pathology. *J Mol Diagn* 2006;8:412–419.
66. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. *Blood* 2002;100:661–665.
67. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). *J Pathol* 2010;220:586–595.
68. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. *Mod Pathol* 2011;24:1157–1168.
69. Morgado JM, Sanchez-Munoz L, Teodosio CG, et al. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. *Mod Pathol* 2012;25:516–521.
70. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. *Int Arch Allergy Immunol* 2012;157:215–225.
71. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. *Medicine (Baltimore)* 1988;67:345–368.
72. Escobedo L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish network on mastocytosis in a series of 145 patients. *J Allergy Clin Immunol* 2009;124:514–521.
73. Pardanani A, Finke C, Abdelrahman RA, et al. Increased circulating IL-2R α (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: A comprehensive cytokine-phenotype study. *Leukemia* 2013;26:1430–1433.
74. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. *Leukemia* 2011;26:951–958.
75. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. *J Allergy Clin Immunol* 2010;125:719–726, 726 e711–726 e714.
76. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. *Bone Marrow Transplant* 2006;37:353–358.
77. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. *J Clin Oncol* 2014;32:3264–3274.

78. Gotlib J, Pardanani A, Akin C, et al. International working Group-myeloproliferative neoplasms research and treatment (IWG-MRT) & European competence network on mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. *Blood* 2013; 121:2393–2401.
79. Kluijn-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. *N Engl J Med* 1992; 326:619–623.
80. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. *Br J Dermatol* 1998;138:489–495.
81. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case. *Leuk Res* 2005;29:131–134.
82. Kolde G, Sunderkotter C, Luger TA. Treatment of urticaria pigmentosa using interferon alpha. *Br J Dermatol* 1995;133:91–94.
83. Lehmann T, Beyeler C, Lammler B, et al. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B. *Br J Rheumatol* 1996;35:898–900.
84. Lehmann T, Lammler B. IFNalpha treatment in systemic mastocytosis. *Ann Hematol* 1999;78: 483–484.
85. Takasaki Y, Tsukasaki K, Jubashi T, et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. *Intern Med* 1998;37:484–488.
86. Weide R, Ehlenz K, Lorenz W, et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. *Ann Hematol* 1996;72:41–43.
87. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. *Leuk Res* 2004;28:249–257.
88. Lippert U, Henz BM. Long-term effect of interferon alpha treatment in mastocytosis. *Br J Dermatol* 1996;134:1164–1165.
89. Petit A, Pulik M, Gaulier A, et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical features and response to interferon alfa therapy. *J Am Acad Dermatol* 1995;32:850–853.
90. Worobec AS, Kirshenbaum AS, Schwartz LB, et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. *Leuk Lymphoma* 1996;22:501–508.
91. Brunel V, Tadriz Z, Cailleres S, et al. [Interferon alpha and pamidronate: A useful combination in the treatment of osteoporosis and systemic mastocytosis]. *Presse Med* 1998;27:64
92. Czarnetzki BM, Algermissen B, Jeep S, et al. Interferon treatment of patients with chronic urticaria and mastocytosis. *J Am Acad Dermatol* 1994;30:500–501.
93. Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: Review of M. D. Anderson cancer center experience. *Am J Hematol* 2004;77:209–214.
94. Delaporte E, Pierard E, Wolthers BG, et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. *Br J Dermatol* 1995;132:479–482.
95. Lippert U, Henz BM. Long-term effect of interferon alpha treatment in mastocytosis.[comment]. *Br J Dermatol* 1996;134:1164–1165.
96. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. *Am J Hematol* 2009;84:790–794.
97. Simon J, Lortholary O, Caillat-Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The french experience and review of the literature. *Pathol Biol (Paris)* 2004;52: 294–299.
98. Bohm A, Sonneck K, Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. *Exp Hematol* 2010;38:744–755.
99. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. *Blood* 2006;107:752–759.
100. Penack O, Sotlar K, Noack F, et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. *Ann Hematol* 2005; 84:692–693.
101. Tefferi A, Li CY, Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. *N Engl J Med* 2001;344:307–309.
102. Kluijn-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. *Blood* 2003;102:4270–4276.
103. Pardanani A, Hoffbr AV, Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. *Leuk Res* 2004;28:127–131.
104. Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French Multicenter Study of 44 Patients. *Blood ASH Annual Meeting Abstracts* 2010;116:1982.
105. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. *Oncogene* 2003;22:660–664.
106. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. *Exp Hematol* 2003;31:686–692.
107. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. *Blood* 2002;99:1741–1744.
108. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. *Lab Invest* 2007;87:365–371.
109. Droogendijk HJ, Kluijn-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. *Cancer* 2006;107:345–351.
110. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. *Leuk Res* 2009;33:1481–1484.
111. Pagano L, Valentini CG, Caira M, et al. Advanced mast cell disease: An Italian hematological multicenter experience. *Int J Hematol* 2008;88:483–488.
112. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Res* 2006;66:473–481.
113. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. *Blood* 2006;108:286–291.
114. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. *Haematologica* 2007;92:1451–1459.
115. Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. *Eur J Clin Invest* 2008;38:869–873.
116. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. *Leuk Res* 2009;33:735–741.
117. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res* 2008;14:3906–3915.
118. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: Four cases. *Eur J Haematol* 2008;80:456–458.
119. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. *Blood* 2005;106: 721–724.
120. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood* 2005;106:2865–2870.
121. Gotlib J, Kluijn-Nelemans H, George T, et al. Midostaurin (PKC412) Demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: Results from the fully accrued global phase 2 CPKC412D2201 trial. *Blood* 2014;124:Abstract 636.
122. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. *PLoS One* 2009; 4:e7258
123. Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. *Am J Hematol* 2010;85:921–925.
124. Moura DS, Sultan S, Georgin-Lavialle S, et al. Depression in patients with mastocytosis: Prevalence, features and effects of masitinib therapy. *PLoS One* 2011;6:e26375

